olmesartan medoxomil has been researched along with Cardiomyopathy, Congestive in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gurusamy, N; Kodama, M; Lakshmanan, AP; Ma, M; Sukumaran, V; Suzuki, K; Veeraveedu, PT; Watanabe, K; Yamaguchi, K | 1 |
1 other study(ies) available for olmesartan medoxomil and Cardiomyopathy, Congestive
Article | Year |
---|---|
Olmesartan medoxomil treatment potently improves cardiac myosin-induced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 mas receptor.
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Animals; Biomarkers; Cardiac Myosins; Cardiomyopathy, Dilated; Endopeptidases; Fibrosis; Gene Expression Regulation; Heart; Hypertrophy, Left Ventricular; Imidazoles; Mitogen-Activated Protein Kinases; Olmesartan Medoxomil; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Rats; Receptors, G-Protein-Coupled; RNA, Messenger; Tetrazoles | 2012 |